Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1392008

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1392008

Nasal Vaccines Market, By Vaccine Type, By Application, By Distribution Channel, By Geography

PUBLISHED:
PAGES: 160 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

The global nasal vaccines market size was valued at US$ 416.8 million in 2023 and is expected to reach US$ 742.6 million by 2030, grow at a Compound Annual Growth Rate (CAGR) of 8.6% from 2023 to 2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 416.8 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 8.60% 2030 Value Projection: US$ 742.6 Mn
Figure 1. Global Nasal Vaccines Market Share (%), by Region, 2023
Nasal Vaccines Market - IMG1

Nasal vaccine is a vaccine administered through the nose that stimulates an immune response without an injection. A vaccine dose is given via nose, rather than orally or through the arm. While several versions of a nasal vaccine are in development, most are in preclinical stages. A nasal vaccine is touted to have the ability to end the cycle of transmission, stop infection, and stop lung damage, including other adverse effects as the dose is administered through the nose, where the virus first enters the body. Thus, market players are focusing on developing safe/effective nasal vaccines.

Market Dynamics:

The rising burden of respiratory diseases or infections, outbreak of COVID-19, increasing focus on the development of safe and effective vaccines, increasing demand for safe and effective vaccines, and increasing research and development activities are the major factors expected to propel the growth of the global nasal vaccines market over the forecast period.

For instance, in January 2023, Bharat Biotech, an Indian-based global biopharmaceutical company announced the launch of India's first intra-nasal COVID-19 vaccine, iNCOVACC for a primary as well as heterologous (mix-and-match) booster dose in India. It was the first nasal COVID-19 vaccine that was approved both as a primary two-dose regimen, and a heterologous booster after two doses of Covishield or Covaxin. It is approved by the Drugs Control General of India (DCGI) as a heterologous booster dose. The new iNCOVACC vaccine can potentially revolutionize the battle against COVID-19 infection.

Key Features of the Study:

  • This report provides an in-depth analysis of the global nasal vaccines market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global nasal vaccines market based on the following parameters, company highlights, products portfolio, key highlights, financial performance, and strategies
  • The key companies covered as a part of this study include AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Serum Institute of India Pvt. Ltd., SINOVAC, Bharat Biotech, Altimmune, FluGen Inc., Vaxart, Intravacc, Gamma Vaccines Pty Ltd., and BioNTech SE
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global nasal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nasal vaccines market

Detailed Segmentation:

  • By Vaccine Type:
    • Live Attenuated Vaccines
    • Inactivated Vaccines
    • Subunit, Recombinant, and Conjugate Vaccines
    • Others (such as DNA Vaccines, Viral Vector Vaccines, etc.)
  • By Application:
    • Influenza
    • COVID-19
    • Other Respiratory Infections (such as RSV, Pneumococcal, etc.)
    • Others (such as Cholera, Typhoid, etc.)
  • By Distribution Channel:
    • Public
    • Private
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • AstraZeneca,
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Serum Institute of India Pvt. Ltd.
    • SINOVAC
    • Bharat Biotech
    • Altimmune
    • FluGen Inc.
    • Vaxart
    • Intravacc
    • Gamma Vaccines Pty Ltd.
    • BioNTech SE
Product Code: CMI5818

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Nasal Vaccines Market, By Vaccine Type
    • Global Nasal Vaccines Market, By Application
    • Global Nasal Vaccines Market, By Distribution Channel
    • Global Nasal Vaccines Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rising burden of respiratory diseases or infections
    • Lack of healthcare infrastructure in developing economies
    • Increasing demand for safe and effective vaccines
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Nasal Vaccines Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Nasal Vaccines Market, By Vaccine Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Live Attenuated Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Inactivated Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Subunit, Recombinant, and Conjugate Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Others (such as DNA Vaccines, Viral Vector Vaccines, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

6. Global Nasal Vaccines Market, By Application, 2020-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Influenza
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • COVID-19
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Other Respiratory Infections (such as RSV, Pneumococcal, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Others (such as Cholera, Typhoid, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

7. Global Nasal Vaccines Market, By Distribution Channel, 2023-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Public
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Private
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Nasal Vaccines Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Serum Institute of India Pvt. Ltd.
  • SINOVAC
  • Bharat Biotech
  • Altimmune
  • FluGen Inc.
  • Vaxart
  • Intravacc
  • Gamma Vaccines Pty Ltd.
  • BioNTech SE
  • Analyst Views

10. Section

  • Research Methodology
  • About us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!